114: Pharmacology Research Institute — Encino, California

114: Pharmacology Research Institute is a clinical research site located in Encino, California, United States 91316.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

114: Pharmacology Research Institute has participated in 1 clinical trials.

Therapeutic areas: Attention Deficit Hyperactivity Disorder.

Sponsors: Arbor Pharmaceuticals, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Encino

Browse all research sites in California · View every site in Encino

• The University of California, Los Angeles
• Encino Hospital Medical Center
• The Retina Partners
• Pharmacology Research Institute
• Research Site
• Encino Research Center
• Novo Nordisk Investigational Site
• T Joseph Raoof Md Inc
• WR-PRI
• HRC Fertility
• Pfizer Investigational Site
• Clinical Research Site

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for 114: Pharmacology Research Institute?

114: Pharmacology Research Institute has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has 114: Pharmacology Research Institute conducted?

114: Pharmacology Research Institute has 1 clinical trials on record. Their work covers Attention Deficit Hyperactivity Disorder.

Is 114: Pharmacology Research Institute accredited by Crixeo Clinical Trials?

114: Pharmacology Research Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about 114: Pharmacology Research Institute?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.